Citi Bruker opened a “90-day positive catalyst watch” on shares of Guardant Health while keeping a Buy rating on the name with a $50 price target ahead of the Q3 report. The analyst views the recent selloff in the shares as “outsized” on both an absolute and relative basis. Heading into Q3 earnings, the firm continues to see “significant conservatism” in the company’s guidance and upside to numbers primarily driven by clinical volumes as well as selling prices.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GH:
- Guardant Health initiated with an Outperform at Bernstein
- WW upgraded, Macy’s downgraded: Wall Street’s top analyst calls
- Piper Sandler upgrades Guardant Health to Overweight following stock selloff
- Guardant Health upgraded to Overweight from Neutral at Piper Sandler
- Guardant Health receives coverage for Guardant Reveal from Geisinger